Crescent Diagnostics appoints Barry Clare as Chairman.
Dublin, Ireland. 9 September 2013. … Crescent Diagnostics Ltd (“Crescent”), a Seroba Kernel portfolio company and a developer of novel tests for predicting osteoporotic fracture risk, is pleased to announce the appointment of Barry Clare as Chairman.
Barry was previously a main board director at The Boots Company PLC, and is currently CEO and Chairman of Healthcare Brands International, and a non-executive director of Wallmark, a major company in the vitamins and supplements business, and is chairman of Vantage Telediagnostics.
Barry joins Crescent Diagnostics as the company prepares to launch Osentia, its over the counter screening tool for osteoporosis, to be sold through pharmacies and other retail outlets. The OTC product, Osentia, will enable customers worried about their risk of developing osteoporosis, to obtain a quick and convenient screen using a nail clipping as the sample. The clipping will be analysed in an NHS laboratory using Crescent’s proprietary technology and the customer will be given a score indicating their potential risk of sustaining a fragility fracture due to osteoporosis.
Brendan Farrell, CEO of Crescent, said: “We are delighted to obtain the services of someone of Barry’s calibre to be our Chairman. As Crescent enters this new stage of its development, Barry’s substantial experience in the OTC sector will be invaluable.”
Barry Clare, Chairman of Crescent, added: “This is a great time to be joining Crescent. The team have done an excellent job in developing Osentia. By using innovative diagnostics technology, Crescent has produced a convenient and affordable osteoporosis screening test, which I am confident will be a major success.”
9 September 2013.
For further information, please contact:
Vicky La Touche-Price, Seroba Kernel Life Sciences.
Tel: +353 1 6334028.